IP Library Granted Patent US 7,943,580
Granted Patent B2
US 7,943,580 · App. 11/793,760 · Granted May 17, 2011

Polypeptide and the use thereof

Assignees: National Cerebral and Cardiovascular Center; Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,580
App. No.
11/793,760
Granted
May 17, 2011
Kind
B2
Abstract

The present invention provides a variety of useful polypeptides. In particular, a polypeptide comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, its amide, or a salt thereof can be used as an agent for preventing/treating hypotension; an agent for preventing/treating obesity, hyperphagia, etc.; an agent for preventing/treating lethargy, time-zone change syndrome (jet lag), etc.; an agent for preventing/treating sterility, etc. A compound or its salt that promotes the activity of a polypeptide comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by any of SEQ ID NOS: 7 to 12 and 37 to 42, its partial peptide, or a salt thereof is useful as an agent for preventing/treating, e.g., menopausal symptoms or hyperthyroidism. A compound or its salt that inhibits the activity of said polypeptide is useful as an agent for preventing/treating, e.g., sterility or hypothyroidism.

Claims (8)

1. An isolated polypeptide, which comprises the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or its amide, or a salt thereof.

2. An isolated polypeptide, which comprises an amino acid sequence at least 90% identical to the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, and has a signal transduction action, or its amide, or a salt thereof.

3. An isolated polypeptide, which comprises an amino acid sequence at least 95% identical to the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, and has a signal transduction action, or its amide, or a salt thereof.

4. An isolated polypeptide, which consists of the amino acid sequence represented by SEQ ID NO: 1, or its amide, or a salt thereof.

5. A medicament comprising the polypeptide according to claim 1 , or its amide, or a salt thereof.

6. A medicament comprising the polypeptide according to claim 2 , or its amide, or a salt thereof.

7. A medicament comprising the polypeptide according to claim 3 , or its amide, or a salt thereof.

8. A medicament comprising the polypeptide according to claim 4 , or its amide, or a salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Mar 2, 2011
From: JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CARDIOVASCULAR CENTER
To: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
Reel/Frame 025886/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2007
From: KANGAWA, KENJI; MORI, KENJI; MIYAZATO, MIKIYA; KOJIMA, MASAYASU
To: JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CARDIOVASCULAR CENTER; TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 019512/0169 →
Priority Claims (1)
JP 2004-374029 · Dec 24, 2004 · national
Continuity (1)
Related Publication 20080124335A1 · May 29, 2008